Skip to main content
. 2021 Mar 4;2021(3):CD013498. doi: 10.1002/14651858.CD013498.pub2
Study ID Intervention(s) and comparator(s) Participants included in analysis
(n) Participants with at least one hypoglycaemic episode
(n) Participants with at least one hypoglycaemic episode
(%) Participants with at least one nocturnal hypoglycaemic episode
(n) Participants with at least one nocturnal hypoglycaemic episode
(% participants) Participants with at least one severe/serious hypoglycaemic episode
(n) Participants with at least one severe/serious hypoglycaemic episode
(%)
Bartley 2008 I: detemir 331 309 93.4 237 71.6 49 14.8
C: NPH 164 159 97.0 124 75.6 42 25.6
BEGIN Basal‐Bolus Type 1 I: degludec 472 451 96 341 72 58a 12
C: glargine 154 147 95 114 74 16 10
BEGIN Flex T1 I: degludec 165 164 99.4 121 73.3 21 12.7
C: glargine 161 156 96.9 117 72.6 16 9.9
BEGIN Young I: degludec  174  171  98.3  133 76.4   31  17.8
C: detemir  175  168  96.0  125 71.4   24  13.8
Bolli 2009 I: glargine 90
C: NPH 85
Chase 2008 I: glargine 85 85 100 55a 64.7 9 10.6
C: NPH/Lente 90 88 97.8 61 67.8 4 4.4
Davies 2014 I: degludec 301 280 93.0 176 58.5 32 10.6
C: detemir 152 139 91.4 89 58.6 16 10.5
Fulcher 2005 I: glargine 62 62a 100 50 81 13a 21
C: NPH 63 59 93.7 54 86 16 25.4
Heller 2009 I: detemir 299 291a 97.3 256a 97.3 54a 18.1
C: glargine 144 140 97.2 121 84.0 23 16.0
Home 2005 I: glargine 292 260 89.0 178 61.0 31 10.6
C: NPH 293 248 84.6 179 61.1 44 15.0
Kobayashi 2007 I: detemir 196 178 92.7 133 69.3 2 1.0
C: NPH 98 95 95.6 78 79.6 3 3.0
Liu 2016 I: glargine 107 99 92.5 83 77.6 1 0.9
C: NPH 54 51 94.4 42 77.8 1 1.9
NCT00595374 I: detemir 75
C: NPH 38
NCT00605137 I: detemir 55 53a 96.4 5 9.1
C: NPH 27 27 100 3 11.1
Pieber 2007 I: detemir 161 120 75.9 47 29.3 3 1.9
C: glargine 159 108 70.1 50 31.4 12 7.8
Porcellati 2004 I: glargine 61 0 0
C: NPH 60 0 0
PRESCHOOL I: glargine 61 61 100 59 96.7 4 6.6
C: NPH 60 63 98.4 60 93.8 2 3.1
Ratner 2000 I: glargine 264 251a 95.1 204a 77.3 23a 8.7
C: NPH 270 254 94.1 208 77.0 28 10.4
Robertson 2007 I: detemir 232 223 96.1 174 75.0 37 15.9
C: NPH 115 113 98.3 101 87.8 23 20.0
Russell‐Jones 2004 I: detemir 491 448 93.3 339 70.6 31 6.5
C: NPH 256 229 92.7 180 72.9 22 8.9
Schober 2002 I: glargine 174 138 79.3 85 48.3 40 25.0
C: NPH 175 138 78.9 89 50.9 50 28.8
Standl 2004 I: detemir 236 184 80.3 134a 58.5 20a 8.7
C: NPH 224 169 76.8 137 62.3 12 5.5
SWITCH 1b I: degludec
C: glargine
Thalange 2013 I: detemir 177 146 82.5 100 56.5 3 1.7
C: NPH 170 150 88.2 111 65.3 12 7.0
Urakami 2017 I: degludec 9 9 100 2 22.2 0 0
C: glargine 9 9 100 4 44.4 0 0
Vague 2003 I: Detemir 301 271 90.0 198 65.8 24 8.0
C: NPH 146 138 94.5 110 75.3 21 14.4
—: denotes not reported
aData from CSR.
bNone of the information for this table was reported before cross‐over.
C: comparator; CSR: clinical study report; I: intervention; N: number of participants; NPH: neutral protamine Hagedorn.